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ABSTRACT
Increasing numbers of women living with HIV are reaching their midlife. We explore the association
of HIV status with sexual function (SF) in women aged 45–60 using two national cross-sectional
surveys: the third British National Survey of Sexual Attitudes and Lifestyles (“Natsal-3”) and
“PRIME”, a survey of women living with HIV attending HIV clinics across England. Both studies
asked the same questions about SF that take account not only sexual diﬃculties but also the
relationship context and overall level of satisfaction, which collectively allowed an overall SF
score to be derived. We undertook analyses of sexually-active women aged 45–60 from Natsal-3
(N = 1228, presumed HIV-negative given the low estimated prevalence of HIV in Britain) and
PRIME (N = 386 women living with HIV). Women living with HIV were compared to Natsal-3
participants using multivariable logistic regression (adjusting for key confounders identiﬁed a
priori: ethnicity, ongoing relationship status, depression and number of chronic conditions) and
propensity scoring. Relative to Natsal-3 participants, women living with HIV were more likely to:
have low overall SF (adjusted odds ratio (AOR) 3.75 [2.15–6.56]), report ≥1 sexual problem(s)
lasting ≥3 months (AOR 2.44 [1.49–4.00]), and report almost all 8 sexual problems asked about
(AORs all ≥2.30). The association between HIV status and low SF remained statistically signiﬁcant
when using propensity scoring (AOR 2.43 [1.68–3.51]). Among women living with HIV (only), low
SF was more common in those who were postmenopausal vs. Premenopausal (55.6% vs. 40.4%).
This study suggests a negative association between HIV status and sexual function in women
aged 45–60. We recommend routine assessment of SF in women living with HIV.
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Introduction
In the UK, approximately 10,500 women of potentially
menopausal age (45–56 years) attended for HIV care
in 2016, a ﬁve-fold increase over ten years (Z Yin, Public
Health England, personal communication, 3 October
2017). Consequently, understanding the eﬀects of the
menopause on women living with HIV is important to
inform HIV-related care.
Studies from the North America, Australia and
Europe have shown that the menopause can contribute
to poor sexual function in women without HIV (Avis
et al., 2017; Dennerstein, Alexander, & Kotz, 2003;
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Mitchell et al., 2013), and is associated with declines
across several domains including desire, lubrication
and orgasm (Çayan et al., 2004; Dennerstein et al.,
2003). Data from Britain’s third National Survey of Sex-
ual Attitudes and Lifestyles (Natsal-3) reveal that almost
one in ten female respondents aged 55–64 reported pain
during sex, with this being associated with postmeno-
pausal status (Mitchell et al., 2017).
Two European studies (both conducted over ten years
ago) have found that between 25–50% of women living
with HIV report sexual problems including poor lubrica-
tion, pelvic pain, and low sexual satisfaction (Bell,
Richardson, Wall, & Goldmeier, 2006; Florence et al.,
2004). An analysis of data from the US Women’s Inter-
agency HIV Study found that women living with HIV
were more likely to report sexual impairment compared
to women without HIV, across all age groups (Wilson
et al., 2010). Qualitative data reveal the importance of
sexual pleasure for older women living with HIV, with
diminished libido and vaginal dryness highlighted as
particularly important (Taylor et al., 2017). Data on sex-
ual function in older women living with HIV remain lim-
ited, and mainly originate from the US or Brazil.
Postmenopausal declines in sexual function and activity
have been shown among women living with HIV in
some of these studies (as also seen in women without
HIV) (Taylor et al., 2015; Wilson et al., 2010), but to
the best of our knowledge no studies have looked at
whether the impact of the menopause on sexual function
diﬀers by HIV status. Genitourinary symptoms are com-
mon, both peri and postmenopausally (Fantry, Zhan,
Taylor, Sill, & Flaws, 2005; Ferreira et al., 2007; Lui-
Filho et al., 2013); one study has found an association
with HIV status (Miller et al., 2005). The only study to
date to examine dyspareunia in menopausal women
with and without HIV did not show any signiﬁcant diﬀer-
ence between the two groups (Valadares et al., 2014).
Using two large, national surveys, we aim to describe
for the ﬁrst time in England (i) the association between
HIV status and sexual function in women aged 45–60,
and (ii) whether any association between menopausal
status and sexual function diﬀers by HIV status.
Methods
We undertook comparative analyses of data from sexu-
ally-active women aged 45–60 in England who partici-
pated in either Natsal-3, to provide a sample of
sexually-active presumed HIV-negative women, or the
PRIME (Positive TRansItions through the MEnopause)
Study, a convenience survey undertaken in HIV clinics
across England, providing a sample of sexually-active
women living with HIV.
Data sources
Natsal-3
Natsal-3 is a one of the largest studies of sexual behav-
iour and lifestyles internationally. It used a multi-stage,
clustered and stratiﬁed probability sample design to
invite men and women aged 16–74 years, living in pri-
vate households in Britain, to participate (Erens et al.,
2014). Data were collected between September 2010
and August 2012, and involved a combination of a
face-to-face interview using computer-assisted personal
interviewing and a self-completion format using compu-
ter-assisted self-interviewing (Erens et al., 2014). A total
of 1715 women aged 45–60 in England participated in
Natsal-3; 1646 had data available on sexual activity in
the past year, of whom 1228 were sexually-active and
provided data on sexual function.
As a survey designed to be broadly representative of the
general population, and given the low estimated prevalence
of HIV in Britain (Brown et al., 2017) and that just three
female participants in a random subsample of 2,665 sexu-
ally-experienced women aged 16–44 years tested positive
for HIV antibody (Sonnenberg et al., 2013), we assume
the number of HIV-positive participants in the Natsal-3
sample used for this study to be negligible.
The PRIME study
The PRIME study is an observational study exploring the
impact of the menopause on the health and wellbeing of
women living with HIV (Tariq, Burns, Gilson, & Sabin,
2019). The study recruited 869 women living with HIV
aged 45–60 attending one of 21 National Health Service
(NHS) HIV clinics in England between February 2016
and June 2017. Participants completed self-administered
paper-based questionnaires (including validated ques-
tions on menopausal status and symptomatology, as
well as sexual function), supplemented with routine
clinical data. This analysis draws upon data from partici-
pants who reported being sexually active in the year prior
to completing the questionnaire and reported data on
sexual function, (n = 386/709, 54.4%).
Eligibility
The analysis was restricted to women aged 45–60 to cap-
ture those undergoingmenopausal transition and tomini-
mise the risk of multicollinearity between age and
menopause status (Taylor et al., 2015). Themeasure of sex-
ual function used in this analysis is only validated in sexu-
ally-active women (Mitchell, Ploubidis, Datta, &Wellings,
2012), hence we restricted our analyses to those reporting
sexual activity (deﬁned as vaginal, oral, or anal sexual inter-
course) in the year prior to questionnaire completion.
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Women from both datasets were excluded from analyses if
they had missing sexual function data as this occurred
infrequently (<5% of each sample).
Variables
Where there were diﬀerences in the wording and/or
response options of some variables, then consensus was
reached among authors (CM, NT, ST) on the best way
to regroup/recode (see supplementary table). There
were no diﬀerences in wording of our outcome variable
(Natsal SF) and key potential confounding variables
such as ethnicity and depression.
Natsal-SF
Sexual function was assessed with the Natsal Sexual
Function (Natsal-SF) questionnaire, a brief 17-item
measure of sexual function in the last year, addressing
speciﬁc sexual problems, sexual partnership-speciﬁc
issues, a self-appraisal of participant’s sex life, and
whether they had sought help/advice about their sex
life. Using this psychometrically-validated and reliable
measure of sexual function enables this study to concep-
tualise sexual function as the extent to which an individ-
ual is able to participate in and enjoy a sexual
relationship rather than focusing simply on physiological
aspects of sexual response and/or clinical diagnoses of
dysfunction. However, Natsal-SF measure scores are
associated with clinical status (deﬁned as receipt of treat-
ment for sexual diﬃculties) (Mitchell et al., 2012). The
Natsal-SF was used in both Natsal-3 and the PRIME
Study, with wording unchanged between both question-
naires. Item non-response in both Natsal-3 and PRIME
was generally low (<5% in Natsal-3; PRIME ∼7%).
The Natsal-SF allows an overall sexual function score to
be derived for sexually-active respondents, which we use as
our primary outcome, alongside the eight individual sexual
problems asked about. We used a previously published
scoring method (Jones et al., 2015), in which scores range
between0 and 38,withhigher scores indicating lower sexual
function. This scorewas then dichotomised using a score≥
13.44 (corresponding to the upper quintile (80th percen-
tile) in theNatsal-3 sample) todenote relatively poor sexual
function (Mitchell et al., 2013).
Menopausal status
Menopausal status was categorised as a binary variable, i.e.,
“premenopausal” and “postmenopausal” fromdataon self-
reported menstrual pattern in each survey. In Natsal-3,
women were categorised as “menopausal” if they were
aged ≥45 years and had been amenorrheic for over one
year (Mitchell et al., 2013), while in the PRIME Study,
women reporting ≥12 months of amenorrhea were
categorised as “postmenopausal”. All other women in
both surveys were categorised as “not menopausal” in
this study. Women were excluded from participating in
the PRIME study if they were on hormonal contraception,
were pregnant or breastfeeding, had a history of hyster-
ectomyor bilateral oophorectomy, or if their lastmenstrual
periodwas >60months prior. This was not the case inNat-
sal-3 as these data were not available.
CD4 count and HIV viral load
Nadir and most recent CD4 count, and HIV viral load
were extracted from routine clinical data where possible,
and available for 62.4%, 89.0% and 95.6% of PRIME par-
ticipants respectively.
Statistical analysis
Analyses were mainly conducted in SPSS 24 (IBM Corp,
released 2016, IBM SPSS Statistics for Mac, Version 24.0,
Armonk, NY), using complex survey methods to take
account of Natsal-3’s design (including that data were
weighted to be broadly representative of the general
population) and that recruitment of PRIME participants
was clustered by clinic. One exception was that we used
Stata version 15.1 (StataCorp LLC, College Station, TX)
for the propensity score matching.
We present percentages with associated 95% conﬁ-
dence intervals (CI), as well as medians and interquartile
ranges (IQR). Chi-squared tests were used to identify
statistically signiﬁcant associations (p < 0.05) between
HIV status (i.e., whether in Natsal-3 or PRIME) and sex-
ual function outcome variables. We identiﬁed a number
of confounding variables a priori from the literature
including age, ethnicity, number of reported chronic
medical conditions, and depression (screened using the
Patient Health Questionnaire-2 or PHQ-2 (Arroll et al.,
2010; Arroll, Khin, & Kerse, 2003)). We used multivari-
able logistic regression models to calculate the odds of
having (e.g.,) relatively poor sexual function in relation
to not, for women with HIV relative to women without
HIV adjusting for these confounders.
Given diﬀerences in the ethnic composition of Natsal-
3 and PRIME samples, we used propensity score adjust-
ment in an eﬀort to further reduce the eﬀects of con-
founding (Austin, 2011). We used Stata’s “pscore”
function to derive a propensity score based on all vari-
ables that potentially confounded the relationship
between sexual function score and HIV status, listed
above, so including but not limited to ethnicity. We
then ﬁtted a multivariable logistic regression model, as
described above but additionally included the propensity
score as a covariate to see if this attenuated the associ-
ation between HIV status and sexual function.
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Finally, we included HIV/menopause status as an
interaction term in the multivariable model of overall
sexual function to explore whether, and if so, how, this
association diﬀered by HIV status.
Ethics committee approval
The PRIME Study had ethical approval from the South East
Coast-Surrey Research Ethics Committee (REF 15/0735).
The Natsal-3 study was approved by the Oxfordshire
Research Ethics Committee A (reference: 09/H0604/27).
Results
Sample characteristics
Women living with HIV were slightly younger than Nat-
sal-3 participants (median age: 49 vs. 51, Table 1).
Approximately 70% of women living with HIV were
black African, whereas 87.5% of Natsal-3 participants
were white British. The majority of women living with
HIV and Natsal-3 participants were in an ongoing
relationship (85.1% and 88.7%, respectively, p = 0.74).
Natsal-3 participants were more likely than women liv-
ing with HIV to be postmenopausal (56.3% vs. 27.8%,
p < 0.001). Almost all women identiﬁed as heterosexual
(97.9% and 99.2% in Natsal-3 and PRIME respectively).
Compared to Natsal-3 participants, women living
with HIV were more likely to report ≥1 chronic con-
dition other than HIV (46.8% vs. 30.0%, respectively, p
< 0.001) and score above the cut-oﬀ point for depression
(22.4% vs. 10.8%, p < 0.001). The majority of women liv-
ing with HIV had an HIV viral load <40 copies/ml (n =
235/256, 91.8%); median last CD4 count was 632 cells/
mm3 (IQR 509-830 cells/mm3). The mean time since
HIV diagnosis was 13.8 years (standard deviation 6.9
years) with a median nadir CD4 count of 189 cells/
mm3 (IQR 78-288 cells/mm3).
Overall sexual function
Compared to Natsal-3 participants, women living with
HIV had lower sexual function according to the Nat-
sal-SF measure (median score: 8.44 vs. 11.59, p <
0.001), with women living with HIV more likely to
score above the cut-oﬀ for low sexual function (22.9%
in Natsal-3 participants vs. 44.6% in women living with
HIV, p < 0.001, Table 2). This remained the case after
adjustment (adjusted odds ratio (AOR) 3.75 [2.15–
6.56]). Using a model additionally including the propen-
sity score, and the association between HIV status and
sexual function was attenuated but remained statistically
signiﬁcant (AOR 2.43 [1.68–3.51]).
In univariable analysis among women living with
HIV, we found no association between sexual function
and nadir CD4 count <350 cells/mm3 (OR 0.64 [0.31–
1.31]); current CD4 count <500 cells/mm3 (OR 0.72
[0.35–1.47]) or having an HIV viral load ≥40 copies/
ml (OR 1.02 [0.39–2.70]). Taking women with an HIV
diagnosis of <10 years as the reference group, women
who had been diagnosed for 10–19 years did not have
increased odds of low sexual function (OR 0.96 [0.53–
1.72]), however those diagnosed for ≥20 years had
over twice the odds of low sexual function (OR 2.44
[1.21–4.90]). This association persisted after adjusting
for age (AOR 2.50 [1.22–5.08]).
Table 1. Sample characteristics of sexually-active participants in
Natsal-3 and PRIME.
Natsal-3 (HIV-)
PRIME (HIV
+)
p-
valued
N = 1228a,
1677b N = 386
n (%)c n (%)
Age (years)e
Median (IQR) 51 (48–55) 49 (47–52) <0.001
Ethnicity
White British 1464 (87.5) 35 (9.3) <0.001
Black African 23 (1.4) 260 (69.1)
White Other 62 (3.7) 20 (5.3)
Black Other 33 (2.0) 37 (9.8)
Other 91 (5.4) 24 (6.4)
Education
No qualiﬁcations 216 (13.0) 33 (8.9) <0.001
O Levels/GCSEsf 647 (38.9) 76 (20.5)
A Levelsg 404 (24.3) 78 (21.1)
University degree or above 396 (23.8) 183 (49.5)
Employment status
Full/part-time employment 1235 (73.8) 280 (74.7) 0.74
No employment 439 (26.2) 95 (25.3)
Ongoing relationship
No 189 (11.3) 57 (14.9) 0.73
Yes 1488 (88.7) 326 (85.1)
Menopause status
Pre-menopausal 727 (43.7) 278 (72.2) <0.001
Post-menopausal 936 (56.3) 107 (27.8)
Number of chronic conditions
(other than HIV)
None 1165 (70.0) 201 (53.2) <0.001
1 404 (24.2) 130 (34.4)
2 77 (4.6) 41 (10.8)
3 16 (1.0) 5 (1.3)
≥4 4 (0.2) 1 (0.3)
Depressive symptoms (PHQ-2)
No (score < 3) 1496 (89.2) 288 (77.6) <0.001
Yes (score ≥ 3) 181 (10.8) 83 (22.4)
Current smoker
No 1346 (80.3) 344 (91.7) <0.001
Yes 331 (19.7) 31 (8.3)
Recreational drug useh
No 1645 (98.1) 366 (96.8) 0.24
Yes 32 (1.9) 12 (3.2)
PRIME data were not weighted. Where the numerators do not add up to the
corresponding denominator, this is due to missing data. IQR, interquartile
range; PHQ, Patient Health Questionnaire.
aUnweighted denominator.
bWeighted denominator.
cWeighted numerator.
dChi-squared p-value for all associations except age.
eMann-Whitney U median test.
fEquivalent to US Grade 10.
gEquivalent to US Grade 12.
hPRIME asked about recreational drug use in the past three months, whereas
Natsal-3 asked in the past year.
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Sexual function problems
Both Natsal-3 participants and women living with HIV
commonly reported having experienced ≥1 sexual pro-
blem lasting ≥3 months in the past year (54.3% and
68.7% respectively, p < 0.001, Table 2). In adjusted ana-
lyses, women living with HIV were more likely to report
≥1 sexual problem in the past year than Natsal-3 partici-
pants (AOR 2.44 [1.49–4.00]).
Each of the eight sexual problems asked about were
more commonly reported by women living with HIV.
For instance, women living with HIV were more likely
than Natsal-3 participants to report a lack of interest in
sex (48.4% vs. 38.3%, AOR 2.30 [1.30–4.07]), the most
commonly-reported sexual problem in both groups.
Vaginal dryness, a common postmenopausal symptom,
was nearly twice as common in women living with
HIV as Natsal-3 participants (28.5 vs. 17.2%, AOR 2.44
[1.47–4.06]). Women living with HIV were much more
likely to report anxiety (16.1% vs. 3.5%, AOR 4.01
[2.24–7.16]), and no excitement or arousal (31.6% vs.
13.1%, AOR 3.50 [1.95–6.30]) during sex.
Association between menopausal status and
sexual function
We found no evidence that low sexual function was
associated with menopausal status in the combined Nat-
sal-3 and PRIME sample (AOR 1.18 [0.88–1.59]). When
looking at the association between menopausal status
and sexual function stratiﬁed by HIV status, we found
no association between menopausal status and low sex-
ual function among Natsal-3 participants (21.3% (95%
CI: 18.6%–24.3%) premenopausal vs. 24.3% (95% CI:
21.8%–26.9%) postmenopausal). Conversely, we did
ﬁnd a statistically signiﬁcant association between
menopausal status and sexual function among women
living with HIV, with 53.3% (95% CI: 42.3%–63.9%) of
post-menopausal women living with HIV having low sex-
ual function compared to 38.2% (95% CI: 28.9%–48.5%)
of premenopausal women living with HIV. However, it
is important to note that we found no evidence that
HIV status modiﬁed the association between menopausal
status and low sexual function (p = 0.15).
Seeking help for one’s sex life
Among sexually-active women who reported experien-
cing ≥1 sexual problem over the past year, women living
with HIV were more likely to seek help about their sex
life (31.7% vs. 17.1%, p < 0.001, Table 3). Women living
Table 2. Prevalence and odds ratios of reporting sexual function problems by sexually-active participants in Natsal-3 and PRIMEa.
Sexual Problems
Natsal-3 (HIV-)
N = 1228b, 1677c
% (95% CI)
PRIME (HIV+)
N = 386
% (95% CI) p-valued
Crude OR
(95% CI)
AORe
(95% CI)
Lacked interest in sex 38.3% (36.1–40.5) 48.4% (41.4–56.6) 0.007 1.51 (1.12–2.04) 2.30 (1.30–4.07)
Lacked enjoyment in sex 13.1% (11.6–14.8) 31.6% (27.4–36.1) <0.001 3.06 (2.39–3.91) 3.50 (1.94–6.30)
Felt anxious during sex 3.5% (2.6–4.6) 16.1% (12.6–20.3) <0.001 5.34 (3.56–8.00) 4.01 (2.24–7.16)
Physical pain as a result of sex 7.5% (6.3–8.9) 15.3% (12.8–18.2) <0.001 2.23 (1.69–2.95) 2.71 (1.83–4.01)
No excitement/ arousal during sex 8.7% (7.5–10.1) 28.8% (23.2–33.3) <0.001 4.07 (3.02–5.49) 3.17 (1.84–5.44)
No orgasm/ took a long time to reach orgasm despite arousal 14.9% (13.2–16.6) 31.1% (26.7–35.8) <0.001 2.59 (2.01–3.32) 2.82 (1.86–4.28)
Reached orgasm too quickly 2.4% (1.8–3.3) 7.4% (4.6–11.2) <0.001 3.15 (1.79–5.54) 2.20 (0.67–7.26)
Vaginal dryness 17.2% (15.5–19.1) 28.5% (24.4–33.0) <0.001 1.91 (1.50–2.45) 2.44 (1.47–4.06)
Experienced at least one problem 54.3% (52.1–56.5) 68.7% (63.8–73.1) <0.001 1.84 (1.46–2.33) 2.44 (1.49–4.00)
Overall sexual functionf Low sexual function 22.9% (21.0-25.0) 44.6% (37.3–52.2) <0.001 2.71 (1.96–3.75) 3.75 (2.15-6.56)
CI, conﬁdence interval; OR, odds ratio; AOR, adjusted odds ratio
aSexually-active participants were those who reported having sex in the past 1 year. Sexual problems were reported from the past year and lasted ≥3 months.
bUnweighted denominator.
cWeighted denominator.
dChi-squared p-value for associations between HIV status and sexual problems variables.
eAdjusted for age, ethnicity, ongoing relationship status, depression and number of chronic conditions.
f Score≥ 13.44 indicated low sexual function.
Table 3. Advice/care-seeking about one’s sex life among
sexually-active participants reporting ≥1 sexual problem(s).
Source of help/advice
Natsal-3 (HIV-)
N = 656a, 910b
% (95% CI)
PRIME (HIV+)
N = 265
% (95% CI)
p-
valuec
Family member/friend 4.6% (3.5–6.0) 12.1% (9.5–15.3) <0.001
Sexual health/ GUM/ STI
clinic
1.3% (0.8–2.1) 12.1% (8.7–16.6) <0.001
Internet 1.8% (1.3–2.6) 7.9% (5.5–11.3) <0.001
GP/Family doctor 10.4% (8.8–12.3) 6.0% (3.7–9.8) 0.03
Self-help books/
information leaﬂets
1.7% (1.2–2.5) 4.9% (3.2–7.4) <0.001
Psychiatrist/psychologist 0.5% (0.3–1.0) 1.9% (1.0–3.6) <0.05
Relationship counsellor 0.7% (0.4–1.3) 1.5% (0.6–3.9) 0.19
Self-help groups N/A 1.1% (0.3–4.8) 0.02
Other type of clinic/
doctor
1.5% (0.8–2.6) 0.8% (0.2–2.9) 0.36
Helpline N/A 0.4% (0.1–2.7) 0.07
Sought help from at
least one source
17.1% (14.9–19.5) 31.7% (26.5–37.4) <0.001
CI, interquartile range; GUM, genitourinary medicine; STI, sexually transmitted
infection; GP, general practitioner.
aUnweighted denominator.
bWeighted denominator.
cChi-squared test.
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with HIV were more likely than Natsal-3 participants to
seek advice from a family member or friend (12.1% vs.
4.6%, p < 0.001), as well as from a sexual health/HIV
clinic (12.1% vs. 1.3%, p < 0.001). On the other hand,
Natsal-3 participants more commonly sought advice
from their GP (6.0% vs. 10.4%, p = 0.03).
Discussion
Our analysis shows that sexual function problems among
sexually-active women aged 45–60 are more common
among women living with HIV, compared to a presumed
HIV-negative group of women of similar age. Women
living with HIV were more likely to exhibit overall low
sexual function and to report ≥1 sexual problem lasting
≥3months in the past year. Lack of interest in sex was the
most prevalent issue reported by both cohorts of women,
although the greatest disparity between the two groups
was seen in anxiety and excitement, and arousal. We
found that postmenopausal status was associated with
low sexual function among women living with HIV,
but not among Natsal-3 participants. This contrasts
with a previous Natsal-3 analysis which found an associ-
ation between menopausal status and sexual function
among Natsal-3 participants aged 16–74 years, likely a
result of the narrower age range used in this present
analysis (Mitchell et al., 2013). Compared with Natsal-
3 participants, women living with HIV were also more
likely to seek informal advice about their sex life from
family and friends, and less likely to seek help from
healthcare providers outside of sexual health. It is unsur-
prising that women living with HIV are more likely to
seek help within sexual health services as in many
parts of the UK, HIV and sexual health services are pro-
vided within the same department aﬀording women the
opportunity to have sexual health issues addressed.
The eﬀects of living with HIV on women’s sexual
well-being are widely recognised (Carter et al., 2017).
We found an association between lower sexual function
and having been diagnosed with HIV for ≥20 years. Pre-
vious research conducted in 1997 has suggested a period
of “psychosexual adjustment” after HIV diagnosis (Han-
kins, Gendron, Tran, Lamping, & Lapointe, 1997). Our
data, from the contemporary antiretroviral therapy era,
suggest that the impact of HIV diagnosis on sexual func-
tion endures longer than previously described. We found
no association between sexual function and nadir CD4
count, current CD4 count or HIV viral load, in keeping
with other studies (Carter et al., 2017). It is therefore
likely that multidimensional contextual factors play an
important role in sexual well-being including the
emotional impact of HIV diagnosis, experiences of
trauma and violence, age, HIV-related stigma, and
concerns about HIV transmission (Carter et al., 2017),
many of which we did not measure in the PRIME
Study. Of particular interest is our ﬁnding that the great-
est disparities between Natsal-3 and PRIME participants
were in reported problems around anxiety and excite-
ment, and arousal. Previous research has identiﬁed fear
of HIV transmission as an important contributing factor
in sexual diﬃculties (El Fane et al., 2011), and it is
reasonable to assume that this impacts both excitement
and arousal.
A recent review concludes that the majority of exist-
ing work on sex in women living with HIV focuses on
either HIV transmission risk or physiological dysfunc-
tion, neglecting broader aspects of sexual well-being
(Carter et al., 2017). Our study addresses a signiﬁcant
evidence gap on the sexual well-being of midlife
women living with HIV and is one of very few compar-
ing sexual function in women with and without HIV.
Our ﬁndings are consistent with the limited previous lit-
erature showing that women living with HIV are more
likely to experience diminished sexual function (Denis
& Sung-Mook, 2003; Wilson et al., 2010), but builds
upon this by focusing on midlife women, a group
whose sexual well-being may be compromised by the
menopause. Furthermore, by focusing on an older
group of women who have been living with HIV for a
median of 13.8 years, we highlight the enduring impact
of HIV on sexual wellbeing beyond the time of diagnosis.
There were demographic diﬀerences between the Nat-
sal-3 and PRIME Study participants; most notably in
terms of ethnicity, reported symptoms of depression,
and other chronic conditions. We took account of
these by using multivariable analyses and propensity
score adjustment, however, there may be some residual
confounding. Literature on ethnic and cultural diﬀer-
ences in women’s sexual function remains limited, with
inconsistent ﬁndings (Laumann, Paik, & Rosen, 1999;
Nazareth, Boynton, & King, 2003; Nicolosi et al.,
2004). Furthermore, we did not have data in both data-
sets on potentially important confounders such as pov-
erty, gender-based violence, and stigma, which could
lead to an overestimation of the eﬀect of HIV status on
sexual function. Another limitation is that eligibility cri-
teria diﬀered between PRIME and Natsal-3; women were
ineligible to participate in PRIME if they reported any-
thing that might disrupt bleeding patterns, including
use of hormonal contraception which may have dispro-
portionately excluded women living with HIV who were
sexually active. This may have led to an underestimation
of low sexual function in this group. Natsal-3 did not
share these eligibility criteria, therefore some women
may have been misclassiﬁed as postmenopausal. We
categorised menopausal status on the basis of self-
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reported menstrual pattern (without biological conﬁr-
mation). Although this approach is well-validated
(Brambilla, Mckinlay, & Johannes, 1994), some women
may have been misclassiﬁed; it is hard to predict whether
and how this might have biased our results. We did not
have a detailed menstrual history from Natsal-3 respon-
dents and were unable to diﬀerentiate between pre and
perimenopausal women. This may have attenuated
diﬀerences observed between pre and postmenopausal
women. We do not know the HIV status of Natsal-3 par-
ticipants in this analysis. Natsal-3 collected urine
samples from a subsample of participants aged 16–44
to test for a range of sexually transmitted infections,
including HIV, and of these 2665 women, only three
tested positive for HIV antibody, giving an estimated
population prevalence of 0·1% (Sonnenberg et al.,
2013). Consequently, we believe it is reasonable to
assume that Natsal-3 female participants aged 45–60
will have a similarly low HIV prevalence. A further poss-
ible limitation is that only sexually active women were
eligible to complete the Natsal-SF measure. This is
because the majority of items asked about problems
that could only arise in the event of sexual activity.
Our analysis therefore does not capture prior problems
that may have led to cessation of sexual activity, or pre-
vented an individual from becoming sexually active. This
may have led to an underestimation of sexual problems,
although we are mindful of not assuming that sexual
inactivity indicates sexual problems. Moreover, we
recognise that sexual activity occurs outside of vaginal,
oral, and anal intercourse.
Our detailed analysis of sexual function in midlife
women living with HIV is one of the largest internation-
ally, and the ﬁrst to date in the UK. It is further strength-
ened by the inclusion of not only a presumed HIV-
negative comparison group, but one that is broadly
representative of the general population. Moreover, by
using the validated Natsal-SF score, we have a multidi-
mensional measure of sexual function that attempts to
go beyond a medicalised model of sexual pathology (Car-
ter et al., 2017).
Our analysis highlights the potential impact of HIV
on midlife women’s sexual function. There is a paucity
of data on the sexual function of women living with
HIV (relative to men living with HIV), and even less
that focus on older women. Future work in women living
with HIV could focus on: biological mechanisms under-
lying reduced sexual function especially during the
menopause transition; exploring the association between
sexual function and quality of life; generating a qualitat-
ive understanding of sexual well-being and pleasure
especially around anxiety, excitement and arousal; and
developing interventions that support the sexual well-
being of women living with HIV. Finally, in light of
data supporting condomless sex in the context of an
undetectable HIV viral load as pertaining to HIV trans-
mission, data on sexual function in the era of Undetect-
able = Untransmittable (U = U) (Rodger et al., 2016) are
warranted, especially regarding fears of transmission and
the consequent impact on desire, excitement and arousal.
Sexual activity is an important factor in the mental
health and quality of life in people across the life-course
(Hinchliﬀ, Tetley, Lee, & Nazroo, 2018; Lee, Vanhoutte,
Nazroo, & Pendleton, 2016). Our ﬁndings highlight that
sexual problems are commonly reported by midlife
women, and that women living with HIV may be at par-
ticular risk. UK data suggest that HIV physicians do not
routinely ask female patients about sexual function (Bell
et al., 2006). Furthermore, a recent survey of UK GPs
revealed low levels of conﬁdence in managing menopau-
sal symptoms in women living with HIV (Chirwa, Ma,
Guallar, & Tariq, 2017). Therefore, sexual problems in
menopausal women living with HIV may go unrecog-
nised and unsupported by healthcare professionals. We
advocate that assessment of sexual function be incorpor-
ated into the routine HIV clinical care provided to
women living with HIV of all ages, and welcome forth-
coming UK guidelines on the sexual and reproductive
healthcare of people living with HIV which recommend
routine annual enquiry about sexual function and meno-
pausal status and symptoms (Waters et al., In press). It is
only by thinking beyond the paradigm of HIV trans-
mission risk, and recognising the importance of women’s
sexual pleasure across the life course, that healthcare pro-
viders can support the sexual and reproductive rights of
older women living with HIV.
Acknowledgments
CM and CS are members of the NIHR Health Protection
Research Unit (NIHR HPRU) in Blood Borne and Sexually
Transmitted Infections at University College London in part-
nership with Public Health England (PHE) and in collabor-
ation with the London School of Hygiene and Tropical
Medicine. The views expressed are those of the authors and
not necessarily those of the NIHR, the Department of Health
and Social Care, the Wellcome Trust, or PHE. NT, CM, KM
and ST conceived and designed this analysis. NT conducted
all analyses and drafted the ﬁrst version of this article, under
the supervision of CM and ST. All authors critically reviewed
the ﬁrst version of the article and approved the ﬁnal draft for
publication. The PRIME Study Expert Advisory Group: Com-
fort Adams, Jane Anderson, Mwenza Blell, Jonathan Elford
(Chair), Janine MacGregor-Read, Fiona Pettitt, Janice
Rymer, Jane Shepherd, Lorraine Sherr, Emily Wandolo. The
PRIME Study Research Team: Saliha Abbassi, Tuhina Bhatta-
charyya and Alexandra Rolland. The PRIME Study recruiting
sites: Barking Community Hospital (Rageshri Dhairyawan,
Emma Macfarlane, Sharmin Obeyesekera, Cecelia Theodore);
AIDS CARE 7
Barts Health NHS Trust (James Hand, Helena Miras, Liat Sar-
ner); Brighton and Sussex University Hospital (Yvonne Gil-
leece, Alyson Knott, Celia Richardson); Chelsea and
Westminster Hospital (Mimi Chirwa, Ann Sullivan, Mini
Thankachen, Sathya Visvendra); City of Coventry Health
Centre (Sris Allen, Kerry Flahive); Guy’s and St Thomas’ Hos-
pital (Julie Fox, Julianne Iwanga, Annemiek DeRuiter, Mark
Taylor); 10 Hammersmith Broadway (Sophie Hobday, Rachael
Jones, Clare Turvey); Homerton University Hospital (Monica
James, Sambasivarao Pelluri, Iain Reeves); Kings College Hos-
pital (Sarah Barber, Priya Bhagwandin, Lucy Campbell, Leigh
McQueen, Frank Post, Selin Yurdakul, Beverley White); Lewi-
sham and Greenwich NHS Trust (Tarik Moussaoui, Melanie
Rosenvinge, Judith Russell); Mortimer Market Centre (Tuhina
Bhattacharya, Alexandra Rolland, Shema Tariq); New Cross
Hospital Wolverhampton (Sarah Milgate, Anjum Tariq);
North Manchester General Hospital (Claire Fox, Gabriella
Lindergard, Andrew Ustianowski); Royal Free Hospital NHS
Trust (Fiona Burns, Nargis Hemat, Nnenna Ngwu, Rimi
Shah); Southend Hospital (Sabri Abubakar, John Day, Laura
Hilton, Henna Jaleel, Tina Penn); St Mary’s Hospital (Angela
Bailey, Nicola Mackie); University Hospital Birmingham
(Reka Drotosne-Szatmari, Jan Harding, Satwant Kaur, Tessa
Lawrence, Monika Oriak, Jonathan Ross); West Middlesex
Hospital (Kimberley Forbes, Ursula Kirwan, Shamela De
Silva, Marie-Louise Svensson, Rebecca Wilkins). Natsal-3 is a
collaboration between University College London (London,
UK), the London School of Hygiene & Tropical Medicine
(London, UK), NatCen Social Research, Public Health Eng-
land (formerly the Health Protection Agency), and the Univer-
sity of Manchester (Manchester, UK). We thank the team of
interviewers from NatCen Social Research. We acknowledge
the support of the steering committee members of the NIHR
HPRU in Blood Borne and Sexually Transmitted Infections:
Caroline Sabin (Director), John Saunders (PHE Lead), Cathe-
rine Mercer, Gwenda Hughes, Jackie Cassell, Greta Rait, Sam-
reen Ijaz, Tim Rhodes, Kholoud Porter, Sema Mandal and
William Rosenberg. Finally, and most importantly, we thank
all our participants for sharing their time and experiences so
generously with us.
Funding
The PRIME Study was funded by the National Institute for
Health Research (NIHR) in the form of a postdoctoral fellow-
ship to ST [grant number PDF-2014-07-071]. Natsal-3 was
supported by grants from the Medical Research Council
[grant number G0701757] and the Wellcome Trust [grant
number 084840], with contributions from the Economic and
Social Research Council and Department of Health. Since Sep-
tember 2015, KM has been supported by the United Kingdom
Medical Research Council [grant number MC_UU_12017/11],
and Scottish Government Chief Scientist Ofﬁce [grant number
SPHSU11]. Since March 2018, ST has received salary support
through a UCL/Wellcome Institutional Strategic Support Fund
Flexible Support Awards (grant number 204841/Z/16/Z).
Declaration of interests
ADR is a full time employee of ViiV Healthcare. AU has
received speaker and advisory board fees from: Abbvie,
Gilead, Janssen, MSD, ViiV Healthcare; research grants
from: Abbvie, Gilead; and has participated in research
programmes for Abbvie, Gilead, Janssen-Cilag, MSD,
and ViiV Healthcare. CS has received funding for mem-
bership of Data Safety and Monitoring Boards, Advisory
Boards, speaker panels and for preparation of edu-
cational materials from Gilead Sciences, ViiV Healthcare
and Janssen-Cilag. FB has received consultancy fees and
conference support from Gilead Sciences. FP reports
grants to King’s College Hospital NHS Foundation
Trust from ViiV Healthcare and Gilead Sciences, and
personal fees from Gilead Sciences, Janssen-Cilag, Glax-
oSmithKline/ViiV Healthcare, and Merck. JR reports
personal fees from GSK Pharma, Hologic Diagnostics
and Janssen Pharma, as well as ownership of shares in
GSK Pharma and AstraZeneca Pharma. RD has received
educational grants from Gilead Sciences and MSD, and
consultation fees from Gilead Sciences. RJ has received
educational grants and personal fees from Gilead
Sciences, MSD, Janssen-Cilag, Abbvie and ViiV Health-
care. ST has previously received a travel bursary funded
by Janssen-Cilag through the British HIV Association,
and speaker honoraria and funding for preparation of
educational materials from Gilead Sciences. YG has
received payment for medical education meetings and
advisory boards from ViiV Healthcare, Gilead Sciences
and MSD. ST, FB and CS are members of the steering
group of SWIFT, a networking group for people involved
in research in HIV and women, funded by Bristol Myers
Squibb. All authors reporting funding from pharma-
ceutical companies conﬁrm that this is outside the sub-
mitted work. For the remaining authors no COI were
declared.
ORCID
Catherine H. Mercer http://orcid.org/0000-0002-4220-5034
Kirstin R. Mitchell http://orcid.org/0000-0002-4409-6601
Mwenza Blell http://orcid.org/0000-0002-6794-3826
Shema Tariq http://orcid.org/0000-0001-9802-7727
References
Arroll, B., Goodyear-Smith, F., Crengle, S., Gunn, J., Kerse, N.,
Fishman, T.,…Hatcher, S. (2010). Validation of PHQ-2
and PHQ-9 to screen for major depression in the primary
care population. The Annals of Family Medicine, 8(4),
348–353.
Arroll, B., Khin, N., & Kerse, N. (2003). Screening for
depression in primary care with two verbally asked ques-
tions: Cross sectional study. Bmj, 327(7424), 1144–1146.
Austin, P. C. (2011). An introduction to propensity score
methods for reducing the eﬀects of confounding in observa-
tional studies.Multivariate Behavioral Research, 46(3), 399–
424.
8 N. TOORABALLY ET AL.
Avis, N. E., Colvin, A., Karlamangla, A. S., Crawford, S., Hess,
R., Waetjen, L. E.,…Greendale, G. A. (2017). Change in
sexual functioning over the menopausal transition: Results
from the study of women’s Health across the Nation.
Menopause (New York, N. Y.), 24(4), 379–390.
Bell, C., Richardson, D., Wall, M., & Goldmeier, D. (2006).
HIV-associated female sexual dysfunction–clinical experi-
ence and literature review. International Journal of STD &
AIDS, 17(10), 706–709.
Brambilla, D. J., Mckinlay, S. M., & Johannes, C. B. (1994).
Deﬁning the perimenopause for application in epidemiolo-
gic investigations. American Journal of Epidemiology, 140
(12), 1091–1095.
Brown, A. E., Kirwan, P. D., Chau, C., Khawam, J., Gill, O. N.,
& Delpech, V. C. (2017). Towards elimination of HIV trans-
mission, AIDS and HIV-related deaths in the UK–2017
report. London: Public Health England.
Carter, A., Greene, S., Money, D., Sanchez, M., Webster, K.,
Nicholson, V.,… Loutfy, M. (2017). The problematization
of sexuality among women living with HIV and a new fem-
inist approach for understanding and enhancing women’s
sexual lives. Sex Roles, 77(11–12), 779–800.
Çayan, S., Akbay, E., Bozlu, M., Canpolat, B., Acar, D., &
Ulusoy, E. (2004). The prevalence of female sexual dysfunc-
tion and potential risk factors that may impair sexual
function in Turkish women. Urologia Internationalis, 72
(1), 52–57.
Chirwa, M., Ma, R., Guallar, C., & Tariq, S. (2017). Managing
menopause in women living with HIV: A survey of primary
care practitioners. Post Reproductive Health, 23(3), 111–115.
Denis, A., & Sung-Mook, H. (2003). Sexual functioning of
women with HIV: A comparison with non-HIV women.
The Canadian Journal of Human Sexuality, 12(2), 97.
Dennerstein, L., Alexander, J. L., & Kotz, K. (2003). The meno-
pause and sexual functioning: A review of the population-
based studies. Annual Review of Sex Research, 14(1), 64–82.
El Fane, M., Bensghir, R., Sbai, S., Chakib, A., Kadiri, N.,
Ayouch, A., & Himmich, H. (2011). Quality of sexual life
for people living with HIV (PLWHA). Sexologies, 20(3),
158–162.
Erens, B., Phelps, A., Clifton, S., Mercer, C. H., Tanton, C.,
Hussey, D.,…Datta, J. (2014). Methodology of the third
British national survey of sexual attitudes and lifestyles
(Natsal-3). Sexually Transmitted Infections, 90(2), 84–89.
Fantry, L. E., Zhan, M., Taylor, G. H., Sill, A. M., & Flaws, J. A.
(2005). Age of menopause and menopausal symptoms in
HIV-infected women. AIDS Patient Care & STDs, 19(11),
703–711.
Ferreira, C. E., Pinto-Neto, A. M., Conde, D. M., Costa-Paiva,
L., Morais, S. S., & Magalhães, J. (2007). Menopause symp-
toms in women infected with HIV: Prevalence and associ-
ated factors. Gynecological Endocrinology, 23(4), 198–205.
Florence, E., Schrooten, W., Dreezen, C., Gordillo, V.,
Schönnesson, L. N., Asboe, D.,… Eurosupport Study
Group, the. (2004). Prevalence and factors associated with
sexual dysfunction among HIV-positive women in
Europe. AIDS Care, 16(5), 550–557.
Hankins, C., Gendron, S., Tran, T., Lamping, D., & Lapointe,
N. (1997). Sexuality in Montreal women living with HIV.
Aids Care, 9(3), 261–272.
Hinchliﬀ, S., Tetley, J., Lee, D., & Nazroo, J. (2018). Older
adults’ experiences of sexual diﬃculties: Qualitative ﬁndings
from the English Longitudinal study on Ageing (ELSA). The
Journal of Sex Research, 55(2), 152–163.
Jones, K. G., Mitchell, K. R., Ploubidis, G. B., Wellings, K.,
Datta, J., Johnson, A. M., & Mercer, C. H. (2015). The
Natsal-SF measure of sexual function: Comparison of
three scoring methods. The Journal of Sex Research, 52(6),
640–646.
Laumann, E. O., Paik, A., & Rosen, R. C. (1999). Sexual
dysfunction in the United States: Prevalence and predictors.
Jama, 281(6), 537–544.
Lee, D. M., Vanhoutte, B., Nazroo, J., & Pendleton, N. (2016).
Sexual health and positive subjective well-being in partnered
older men and women. Journals of Gerontology Series B:
Psychological Sciences and Social Sciences, 71(4), 698–710.
Lui-Filho, J. F., Valadares, A. L. R., Gomes, D. d. C., Amaral, E.,
Pinto-Neto, A. M., & Costa-Paiva, L. (2013). Menopausal
symptoms and associated factors in HIV-positive women.
Maturitas, 76(2), 172–178.
Miller, S. A., Santoro, N., Lo, Y., Howard, A. A., Arnsten, J. H.,
Floris-Moore, M.,… Schoenbaum, E. E. (2005). Menopause
symptoms in HIV-infected and drug-using women.
Menopause (New York, N. Y.), 12(3), 348–356.
Mitchell, K. R., Geary, R., Graham, C. A., Datta, J., Wellings, K.,
Sonnenberg, P.,… Jones, K. G. (2017). Painful sex (dyspareu-
nia) in women: Prevalence and associated factors in a British
population probability survey. BJOG: An International
Journal of Obstetrics & Gynaecology, 124(11), 1689–1697.
Mitchell, K. R., Mercer, C. H., Ploubidis, G. B., Jones, K. G.,
Datta, J., Field, N.,…Wellings, K. (2013). Sexual function
in Britain: Findings from the third National survey of sexual
Attitudes and Lifestyles (Natsal-3). The Lancet, 382(9907),
1817–1829. doi:10.1016/S0140-6736(13)62366-1
Mitchell, K. R., Ploubidis, G. B., Datta, J., & Wellings, K.
(2012). The Natsal-SF: A validated measure of sexual func-
tion for use in community surveys. European Journal of
Epidemiology, 27(6), 409–418.
Nazareth, I., Boynton, P., & King, M. (2003). Problems with
sexual function in people attending London general prac-
titioners: Cross sectional study. Bmj, 327(7412), 423.
Nicolosi, A., Laumann, E. O., Glasser, D. B., Moreira, Jr E. D.,
Paik, A., & Gingell, C. (2004). Sexual behavior and sexual
dysfunctions after age 40: The global study of sexual atti-
tudes and behaviors. Urology, 64(5), 991–997.
Rodger, A. J., Cambiano, V., Bruun, T., Vernazza, P., Collins,
S., Van Lunzen, J.,… Beloukas, A. (2016). Sexual activity
without condoms and risk of HIV transmission in sero-
diﬀerent couples when the HIV-positive partner is using
suppressive antiretroviral therapy. Jama, 316(2), 171–181.
Sonnenberg, P., Clifton, S., Beddows, S., Field, N., Soldan, K.,
Tanton, C.,… Johnson, A. M. (2013). Prevalence, risk fac-
tors, and uptake of interventions for sexually transmitted
infections in Britain: Findings from the national surveys
of sexual attitudes and lifestyles (Natsal). The Lancet, 382
(9907), 1795–1806.
Tariq, S., Burns, F., Gilson, R., & Sabin, C. A. (2019). The
PRIME (positive transitions through the menopause)
study: A protocol for a mixed-methods study investigating
the impact of the menopause on the health and well-being
of women living with HIV in England. BMJ Open, 9(6),
e025497.
Taylor, T. N., Munoz-Plaza, C. E., Goparaju, L., Martinez, O.,
Holman, S., Minkoﬀ, H. L.,…Golub, E. T. (2017). “The
AIDS CARE 9
pleasure is better as i’ve gotten older”: Sexual health,
sexuality, and sexual risk behaviors among older women
living with HIV. Archives of Sexual Behavior, 46(4), 1137–
1150.
Taylor, T. N., Weedon, J., Golub, E. T., Karpiak, S. E., Gandhi,
M., Cohen, M. H.,…Goparaju, L. (2015). Longitudinal
trends in sexual behaviors with advancing age and meno-
pause among women with and without HIV-1 infection.
AIDS and Behavior, 19(5), 931–940.
Valadares, A. L. R., Pinto-Neto, A. M., de C Gomes, D.,
D’Avanzo, W. C., Moura, A. S., Costa-Paiva, L., & de
Sousa, M. H. (2014). Dyspareunia in HIV-positive and
HIV-negative middle-aged women: A cross-sectional
study. BMJ Open, 4(11), e004974.
Waters, L., Lord, E., Mackie, N., Melvin, L., Ashby, J., Babu, C.,
…Gilleece, Y. (In press). BHIVA/BASHH/FSRH guidelines
for the sexual & reproductive health of people living with
HIV.
Wilson, T. E., Jean-Louis, G., Schwartz, R., Golub, E. T.,
Cohen, M. H., Maki, P.,…Goparaju, L. (2010). HIV infec-
tion and women’s sexual functioning. Journal of Acquired
Immune Deﬁciency Syndromes (1999), 54(4), 360.
10 N. TOORABALLY ET AL.
